Valuation : Natera, Inc.

Market Cap 47.31B 40.71B 38.3B 34.99B 65.45B 4,466B 65.63B 453B 176B 2,292B 178B 174B 7,382B P/E 2026 *
-239x
P/E 2027 * -38,160x
Enterprise Value 46.24B 39.79B 37.43B 34.2B 63.97B 4,366B 64.14B 442B 172B 2,240B 174B 170B 7,216B EV / Sales 2026 *
15.9x
EV / Sales 2027 * 13.2x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.16%
1 week+0.59%
Current month+1.93%
1 month+19.50%
3 months+52.42%
6 months+66.47%
Current year+43.25%
1 week 316
Extreme 316
332
1 month 305
Extreme 305
343.18
Current year 181
Extreme 181
343.18
1 year 157.42
Extreme 157.425
343.18
3 years 36.9
Extreme 36.9
343.18
5 years 26.1
Extreme 26.1
343.18
10 years 7.35
Extreme 7.35
343.18
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Executive/Senior Manager

-15,160 0.0106%
01/09/26 Sell

Chief Executive Officer

-1,698 0.0012%
10/08/26 Sell

Founder

-6,000 0.0042%
Change 5-day change 1-year change 3-year change Capi.($)
+0.16%+0.59%+95.32%+452.21% 47.31B
-1.39%-2.45%+17.30%+59.89% 26.51B
+1.24%-2.50%-14.82%-39.67% 6.96B
-1.22%-1.21%+3.22%+136.71% 5.8B
-2.48%-2.78%+15.55%+70.23% 3.32B
-1.60%-0.40%-35.12%+1,867.73% 2.56B
-0.46%-3.71%+117.79%+22.48% 2.23B
+7.98%+6.89%+27.90%+40.95% 2.14B
+0.45%-2.63%-13.48%-53.93% 1.84B
-0.82%+2.80%+34.86%+201.66% 1.63B
Average +0.19%-0.69%+24.85%+275.83% 10.03B
Weighted average by Cap. -0.24%-0.46%+51.84%+287.98%

Financials

2026 *2027 *
Net sales 2.91B 2.5B 2.35B 2.15B 4.02B 274B 4.03B 27.79B 10.78B 141B 10.91B 10.67B 453B 3.48B 2.99B 2.82B 2.57B 4.82B 329B 4.83B 33.3B 12.92B 169B 13.07B 12.78B 543B
Net income -193M -166M -156M -143M -267M -18.22B -268M -1.85B -716M -9.35B -724M -709M -30.11B 9.13M 7.85M 7.39M 6.75M 12.63M 862M 12.66M 87.33M 33.89M 442M 34.28M 33.53M 1.42B
Net Debt -1.07B -919M -865M -790M -1.48B -101B -1.48B -10.22B -3.97B -51.74B -4.01B -3.92B -167B -1.36B -1.17B -1.1B -1.01B -1.89B -129B -1.89B -13.04B -5.06B -66.03B -5.12B -5.01B -213B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
04/09/26 $328.18 +0.16% 968,221
03/09/26 $327.67 +0.77% 711,938
02/09/26 $325.17 +1.37% 1,033,232
01/09/26 $320.76 -0.37% 1,208,845
31/08/26 $321.96 -1.32% 1,326,118
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
328.18USD
Average target price
338.07USD
Spread / Average Target
+3.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock